Business
Adial is developing AD04 as a genetically targeted therapy candidate for alcohol use disorder.
Adial reduced losses and improved equity, but AD04 remains pre-revenue with a going-concern warning.
The read at a glance✓ Audited against SEC data
- Business mix — AD04 for alcohol use disorderNote
- Revenue — No revenue in our filing dataNote
- Profitability — Net loss improved to $8.0MOK
- Cash burn — Cash from operations improved to -$6.5MOK
- Balance sheet — Equity +29.7% to $5.3MOK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Going-concern warningWatch
Last 12 months to 30 Jun 2026: net income -$57.8M; changes are against the 12 months before. Insiders, last 12 months: 0 open-market purchases, 0 sales. Computed from the filings; the analysis is from the FY2025 annual report.
Leadership changes
From Azora Therapeutics, Inc. (DE)'s own filings, the day they're filed.
- Aida Habtezion · Director · appointmenteff. 2026-11-03
- Paul Hastings · Director · appointmenteff. 2026-11-03
- Thomas Soloway · Director · appointmenteff. 2026-11-03
Latest filings
- 8-K · Company announcement2026-11-09
- 8-K · Company announcement2026-10-28
- 8-K · Company announcement2026-10-16
- 8-K · Company announcement2026-10-02
- 8-K · Company announcement2026-09-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Azora Therapeutics, Inc. (DE), every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.